A 34-Year-Old Man with Headache, Diploplia, and Hemiparesis
Neurol 86:e28, Lincoln, M.R.,et al, 2016
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Cortical Pathology in Multiple Sclerosis Patients with Epilepsy: A 3 Year Longitudinal Study
JNNP 83:49-54, Calabrese, M.,et al, 2012
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011
Memantine Induces Reversible Neurologic Impairment in Patients with MS
Neurol 72:1630-1633, Villoslada,P.,et al, 2009
Rapidly Progressive Dementia
Ann Neurol 64:97-108, Geschwind,M.D.,et al., 2008
Multiple Sclerosis and Cannabis: A Cognitive and Psychiatric Study
Neurol 71:164-169, Ghaffar,O. &Feinstein,A., 2008
Differential Diagnosis of Bilateral Thalamic Lesions
Clin Neuroradiol 17:3-22, Linn,J.,et al, 2007
Gray and White Matter Brain Atrophy and Neuropsychological Impairment in Multiple Sclerosis
Neurol 66:685-692, Sanfilipo,M.P.,et al, 2006
Comparisons of Patient Self-report, Neurologic Examination, and Functional Impairment in MS
Neurol 56:934-937, Hoogervorst,E.L.J.,et al, 2001
Neuropsychological Status in Multiple Sclerosis after Treatment with Glatiramer
Arch Neurol 56:319-324, Weinstein,A.,et al, 1999
Retinocochleocerebral Vasculopathy
Medicine 77:12-40, Petty,G.W.,et al, 1998
Serial Neuropsychological Assess & Magnetic Resonance Imagingf Analysis in Multiple Sclerosis
Arch Neurol 54:1018-1025, Hohol,M.J.,et al, 1997
Clinicopath Conf
Demyelinating Disease, Case 8-1996, NEJM 334:715-720996., , 1996
Low-Dose Oral Methotrexate in Chronic Progressive Multiple Sclerosis:Analyses of Serial MRIs
Neurol 47:1153-1157, Goodkin,D.E.,et al, 1996
The Effects of 4-Aminopyridine in MS Pts:Randomized, Placebo-Controlled, Double-Blind, Concentration-Controlled, Crossover
Neurol 44:1054-1059, Bever,C.T.,et al, 1994
Information Processing Efficiency in Chronic Fatigue Syndromes and Multiple Sclerosis
Arch Neurol 50:301-304, DeLuca,J.,et al, 1993
Event-Related Potential P300 in MS, Relation to Magnetic Resonance Imaging and Cognitive Impairment
Arch Neurol 49:44-50, Honig,L.S.,et al, 1992
Cognitive Dysfunction in MS, II. Impact on Employment and Social Functioning
Neurol 41:692-696, Rao,S.M.,et al, 1991
Clinicopath Conf
Acute Multiple Sclerosis, Case Record 42-1990, NEJM 323:1123-1135990., , 1990
Cognitive Loss in Multiple Sclerosis
Arch Neurol 46:162-167, Franklin,G.M.,et al, 1989
Correlation of Magnetic Resonance Imaging with Neuropsychological Testing in Multiple Sclerosis
Neurol 39:161-166, Rao,S.M.,et al, 1989
Lyme Neuroborreliosis:Central Nervous System Manifestations
Neurol 39:753-759, Halperin,J.J.,et al, 1989
Correlation of Neuropsychological and MRI Findings in Chronic/Progressive Multiple Sclerosis
Neurol 38:1826-1829, Franklin,G.M.,et al, 1988
Cerebral Magnetic Resonance Imaging Findings in MS, Relation to Affect, Drive and Cognition
Arch Neurol 45:1114-1116, Reischies,F.M.,et al, 1988
Disease Activity & Emotional State in Multiple Sclerosis
Ann Neurol 13:573-577, Dalos,N.P.,et al, 1983
Evoked Potentials in Neurological Diagnosis
BMJ 285:1678-1679, Mastaglia,F.L.,et al, 1982
Psychological Profiles in Patients With Multiple Sclerosis, A Preliminary Investigation
Arch Neurol 37:437-440, Peyser,J.M.,et al, 1980
Cognitive Function in Patients With Multiple Sclerosis
Arch Neurol 37:577-579, Peyser,J.M.,et al, 1980
Herpes Simplex & the Human Nervous System
Milit Med 140:765, Finelli,P.F., 1975
Neuro CPC of MGH
Multiple Sclerosis, Cerebral Infarcts, & Colitis, NEJM 268:607-615., , 1963
Association of Very Early treatment Initiation with the Risk of Long-Term Disability in Patients with a First Demyelinating Event
Neurol 101:e1280-e1292, 549, Cobo-Calvo,A.,et al, 2023
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Diet Quality is Associated with Disability and Symptom Severity in Multiple Sclerosis
Neurol 90:e1-e11, Fitzgerald, K.C.,et al, 2018
Prodromal Symptoms of Multiple Sclerosis in Primary Care
Ann Neurol 83:1162-1173, Disanto,G.,et al, 2018
Numb Chin Syndrome
UptoDate.com Sept, Robertson, C.E., 2018
Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
The Contemporary Spectrum of Multiple Sclerosis Misdiagnosis
Neurol 87:1393-1399, Solomon, A.J.,et al, 2016
Acute Idiopathic Transverse Myelitis in Children
Neurol 84:341-349,332, Deiva, K.,et al, 2015
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Disability in Multiple Sclerosis
Neurol 80:1018-1024, Kister, I.,et al, 2013
Association Between Immediate Initiation of Intramuscular Interferon Beta-1a at the Time of a Clinically Isolated Syndrome and Long-term Outcomes
Arch Neurol 69:183-190, Kinkel,R.P.,et al, 2012
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
NEJM 367:1098-1106,1149, Gold, R.,et al, 2012
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
Increased Tissue Damage and Lesion Volumes in African Americans with Multiple Sclerosis
Neurol 74:538-544,532, Weinstock-Guttman,B.,et al, 2010
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010